Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...

THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC) options could extend overall survival (OS) to 16.9 months according to ...

MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive updated data from its THIO-101 ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, ...

A new wave of hope is sweeping across Europe and MENA for millions of cancer patients seeking affordable and effective treatment options. The rise of generic oncology drugs is offering a much-needed ...

Bitcoin (BTC) rose to nearly $103,000 to usher gains across the crypto market on Tuesday after breakthroughs from China’s DeepSeek led to a steep fall in U.S. indexes on Monday, prompted by ...

Chemotherapy for lung cancer is used for different purposes depending on the type and stage of cancer you have. This includes achieving cancer remission, shrinking a tumor before surgery, killing ...

Although chemotherapy is an effective cancer treatment, it's not recommended for everyone. While most individuals with cancer are offered chemotherapy as part of their treatment plan, there are times ...

Doctors have used chemotherapy (chemo) to treat cancer since the 1940s. The advantage of these drugs is they kill cancer cells throughout your body. One downside is the side effects they can ...